Cargando…

Diversity of malignancies in patients with different types of inborn errors of immunity

Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavakol, Marzieh, Delavari, Samaneh, Salami, Fereshte, Ansari, Sarina, Rasouli, Seyed Erfan, Chavoshzadeh, Zahra, Sherkat, Roya, Ahanchian, Hamid, Aleyasin, Soheila, Esmaeilzadeh, Hossein, Moazzen, Nasrin, Shafiei, Alireza, Abolnezhadian, Farhad, Iranparast, Sara, Ebrahimi, Sareh sadat, Moeini Shad, Tannaz, Pashangzadeh, Salar, Nazari, Farzad, Rezaei, Arezou, Saeedi-Boroujeni, Ali, Nabavi, Mohammad, Arshi, Saba, Fallahpour, Morteza, Bemanian, Mohammad hassan, Sharafian, Samin, Shokri, Sima, Eshaghi, Sarvin, Nazari, Shiva, Shamsian, Bibi Shahin, Dargahi Mal-Amir, Mehrdad, Khazaei, Roya, Ashkevari, Pooya, Khavandegar, Armin, Haghi, Sabahat, Esmaeili, Marzie, Abolhassani, Hassan, Rezaei, Nima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743521/
https://www.ncbi.nlm.nih.gov/pubmed/36510326
http://dx.doi.org/10.1186/s13223-022-00747-2
_version_ 1784848740251598848
author Tavakol, Marzieh
Delavari, Samaneh
Salami, Fereshte
Ansari, Sarina
Rasouli, Seyed Erfan
Chavoshzadeh, Zahra
Sherkat, Roya
Ahanchian, Hamid
Aleyasin, Soheila
Esmaeilzadeh, Hossein
Moazzen, Nasrin
Shafiei, Alireza
Abolnezhadian, Farhad
Iranparast, Sara
Ebrahimi, Sareh sadat
Moeini Shad, Tannaz
Pashangzadeh, Salar
Nazari, Farzad
Rezaei, Arezou
Saeedi-Boroujeni, Ali
Nabavi, Mohammad
Arshi, Saba
Fallahpour, Morteza
Bemanian, Mohammad hassan
Sharafian, Samin
Shokri, Sima
Eshaghi, Sarvin
Nazari, Shiva
Shamsian, Bibi Shahin
Dargahi Mal-Amir, Mehrdad
Khazaei, Roya
Ashkevari, Pooya
Khavandegar, Armin
Haghi, Sabahat
Esmaeili, Marzie
Abolhassani, Hassan
Rezaei, Nima
author_facet Tavakol, Marzieh
Delavari, Samaneh
Salami, Fereshte
Ansari, Sarina
Rasouli, Seyed Erfan
Chavoshzadeh, Zahra
Sherkat, Roya
Ahanchian, Hamid
Aleyasin, Soheila
Esmaeilzadeh, Hossein
Moazzen, Nasrin
Shafiei, Alireza
Abolnezhadian, Farhad
Iranparast, Sara
Ebrahimi, Sareh sadat
Moeini Shad, Tannaz
Pashangzadeh, Salar
Nazari, Farzad
Rezaei, Arezou
Saeedi-Boroujeni, Ali
Nabavi, Mohammad
Arshi, Saba
Fallahpour, Morteza
Bemanian, Mohammad hassan
Sharafian, Samin
Shokri, Sima
Eshaghi, Sarvin
Nazari, Shiva
Shamsian, Bibi Shahin
Dargahi Mal-Amir, Mehrdad
Khazaei, Roya
Ashkevari, Pooya
Khavandegar, Armin
Haghi, Sabahat
Esmaeili, Marzie
Abolhassani, Hassan
Rezaei, Nima
author_sort Tavakol, Marzieh
collection PubMed
description Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the specific mutant gene underlying IEI. We investigated 3056 IEI patients registered in the Iranian national registry between the years 1999 and 2020 in this retrospective cohort study. The frequency of malignancy and its association with the type of IEI in these patients were evaluated. A total of 82 IEI patients with malignancy were enrolled in this study. Among them, predominantly lymphoma was the most common type of malignancy (67.1%), followed by leukemia (11%), and cancers of the head and neck (7.3%). Among identified lymphoma cancers, non-Hodgkin’s lymphomas were the most frequent type (43.9%) followed by different subtypes of Hodgkin’s lymphoma (23.2%). Solid tumors (18.3%) appeared to be very heterogeneous by type and localization. The correlation between the type of malignancy and survival status and the association between the type of malignancy and IEI entities were unremarkable. The awareness of the association between the presence of IEI and cancer highlights the importance of a synergistic effort by oncologists and immunologists in the early diagnosis of malignancy and personalized therapeutic strategies in IEI patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13223-022-00747-2.
format Online
Article
Text
id pubmed-9743521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97435212022-12-13 Diversity of malignancies in patients with different types of inborn errors of immunity Tavakol, Marzieh Delavari, Samaneh Salami, Fereshte Ansari, Sarina Rasouli, Seyed Erfan Chavoshzadeh, Zahra Sherkat, Roya Ahanchian, Hamid Aleyasin, Soheila Esmaeilzadeh, Hossein Moazzen, Nasrin Shafiei, Alireza Abolnezhadian, Farhad Iranparast, Sara Ebrahimi, Sareh sadat Moeini Shad, Tannaz Pashangzadeh, Salar Nazari, Farzad Rezaei, Arezou Saeedi-Boroujeni, Ali Nabavi, Mohammad Arshi, Saba Fallahpour, Morteza Bemanian, Mohammad hassan Sharafian, Samin Shokri, Sima Eshaghi, Sarvin Nazari, Shiva Shamsian, Bibi Shahin Dargahi Mal-Amir, Mehrdad Khazaei, Roya Ashkevari, Pooya Khavandegar, Armin Haghi, Sabahat Esmaeili, Marzie Abolhassani, Hassan Rezaei, Nima Allergy Asthma Clin Immunol Research Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the specific mutant gene underlying IEI. We investigated 3056 IEI patients registered in the Iranian national registry between the years 1999 and 2020 in this retrospective cohort study. The frequency of malignancy and its association with the type of IEI in these patients were evaluated. A total of 82 IEI patients with malignancy were enrolled in this study. Among them, predominantly lymphoma was the most common type of malignancy (67.1%), followed by leukemia (11%), and cancers of the head and neck (7.3%). Among identified lymphoma cancers, non-Hodgkin’s lymphomas were the most frequent type (43.9%) followed by different subtypes of Hodgkin’s lymphoma (23.2%). Solid tumors (18.3%) appeared to be very heterogeneous by type and localization. The correlation between the type of malignancy and survival status and the association between the type of malignancy and IEI entities were unremarkable. The awareness of the association between the presence of IEI and cancer highlights the importance of a synergistic effort by oncologists and immunologists in the early diagnosis of malignancy and personalized therapeutic strategies in IEI patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13223-022-00747-2. BioMed Central 2022-12-12 /pmc/articles/PMC9743521/ /pubmed/36510326 http://dx.doi.org/10.1186/s13223-022-00747-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tavakol, Marzieh
Delavari, Samaneh
Salami, Fereshte
Ansari, Sarina
Rasouli, Seyed Erfan
Chavoshzadeh, Zahra
Sherkat, Roya
Ahanchian, Hamid
Aleyasin, Soheila
Esmaeilzadeh, Hossein
Moazzen, Nasrin
Shafiei, Alireza
Abolnezhadian, Farhad
Iranparast, Sara
Ebrahimi, Sareh sadat
Moeini Shad, Tannaz
Pashangzadeh, Salar
Nazari, Farzad
Rezaei, Arezou
Saeedi-Boroujeni, Ali
Nabavi, Mohammad
Arshi, Saba
Fallahpour, Morteza
Bemanian, Mohammad hassan
Sharafian, Samin
Shokri, Sima
Eshaghi, Sarvin
Nazari, Shiva
Shamsian, Bibi Shahin
Dargahi Mal-Amir, Mehrdad
Khazaei, Roya
Ashkevari, Pooya
Khavandegar, Armin
Haghi, Sabahat
Esmaeili, Marzie
Abolhassani, Hassan
Rezaei, Nima
Diversity of malignancies in patients with different types of inborn errors of immunity
title Diversity of malignancies in patients with different types of inborn errors of immunity
title_full Diversity of malignancies in patients with different types of inborn errors of immunity
title_fullStr Diversity of malignancies in patients with different types of inborn errors of immunity
title_full_unstemmed Diversity of malignancies in patients with different types of inborn errors of immunity
title_short Diversity of malignancies in patients with different types of inborn errors of immunity
title_sort diversity of malignancies in patients with different types of inborn errors of immunity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743521/
https://www.ncbi.nlm.nih.gov/pubmed/36510326
http://dx.doi.org/10.1186/s13223-022-00747-2
work_keys_str_mv AT tavakolmarzieh diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT delavarisamaneh diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT salamifereshte diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT ansarisarina diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT rasouliseyederfan diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT chavoshzadehzahra diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT sherkatroya diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT ahanchianhamid diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT aleyasinsoheila diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT esmaeilzadehhossein diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT moazzennasrin diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT shafieialireza diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT abolnezhadianfarhad diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT iranparastsara diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT ebrahimisarehsadat diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT moeinishadtannaz diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT pashangzadehsalar diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT nazarifarzad diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT rezaeiarezou diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT saeediboroujeniali diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT nabavimohammad diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT arshisaba diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT fallahpourmorteza diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT bemanianmohammadhassan diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT sharafiansamin diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT shokrisima diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT eshaghisarvin diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT nazarishiva diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT shamsianbibishahin diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT dargahimalamirmehrdad diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT khazaeiroya diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT ashkevaripooya diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT khavandegararmin diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT haghisabahat diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT esmaeilimarzie diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT abolhassanihassan diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity
AT rezaeinima diversityofmalignanciesinpatientswithdifferenttypesofinbornerrorsofimmunity